Business Standard

Strides Pharma posts Rs 43 cr Q4 profit vs Rs 207 cr loss a year ago

Company to launch generic products to aid Covid-19 treatment in India, first being Liposomal Amphotericin B to treat black fungus

Strides Pharma Science, Chief Executive Officer R ANANTHANARAYANAN
Premium

R Ananthanarayanan, Managing Director and CEO of the company

Samreen Ahmad Bengaluru
Riding on strong sales, Strides Pharma Science has reported a consolidated net profit of Rs 43.74 crore in the fourth quarter of FY20. The company had posted a consolidated net loss of Rs 206.57 crore in the corresponding quarter a year ago.

Revenue from operations in the fourth quarter stood at Rs 908.49 crore which was at Rs 618.64 crore in the year-ago period.

“Amidst a tough operating environment, we are pleased to have delivered a healthy performance across all businesses in FY21. Our regulated markets franchise which now contributes 80 per cent of revenues has seen significant ramp up

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in